title: Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls.
abstract: The positron emission tomography (PET) ligand [(11)C]DASB is currently the most widely used imaging agent for quantitative studies of the serotonin transporter (SERT) in human brain. The aim of this work was to assess the effects of an intravenous infusion of 10 mg citalopram, a selective serotonin reuptake inhibitor (SSRI), before the PET scan on the kinetics of [(11)C]DASB in arterial plasma and in selected brain regions. Four healthy male volunteers underwent two PET scans with a mean of 523 MBq injected activity after either placebo or citalopram infusion in a randomised design. The citalopram infusion led to a substantial increase of the area under the curve of the metabolite-corrected arterial plasma input function. Total volumes of distribution V(T) were estimated applying the Logan plot to regional time-activity curves or by generating parametric maps with spectral analysis. A mean reduction of the cerebellar V(T) of 19% with Logan analysis and of 24% with spectral analysis was observed after citalopram infusion, which confirms previous findings of displaceable SERT ligand binding in cerebellar grey matter. The SERT occupancy for six target regions with moderate to high binding was 60% derived from BP(ND) and 69% derived from BP(P).
authors.affiliation: Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK. rainer.hinz@manchester.ac.uk
authors.forename: Rainer
authors.initials: R
authors.lastname: Hinz
authors.forename: Sudhakar
authors.initials: S
authors.lastname: Selvaraj
authors.forename: N Venkatesha
authors.initials: NV
authors.lastname: Murthy
authors.forename: Zubin
authors.initials: Z
authors.lastname: Bhagwagar
authors.forename: Matthew
authors.initials: M
authors.lastname: Taylor
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Cowen
authors.forename: Paul M
authors.initials: PM
authors.lastname: Grasby
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001596:Benzylamines / Q000493:pharmacokinetics*; D002531:Cerebellum / Q000098:blood supply / Q000378:metabolism*; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D015283:Citalopram / Q000008:administration & dosage*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011485:Protein Binding / Q000187:drug effects; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*
chemical_list: D001596:Benzylamines; D015283:Citalopram; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C420885:N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine; C493230:SLC6A4 protein, human